Addressing large, unmet global markets with innovative proprietary products More »
Capitalizing on high-value, emerging markets for pharmaceutical and diagnostic products More »
Identifying early-stage companies with potential to increase value for shareholders More »
OPKO continues to make progress with its program to build a company capable of long-term growth and increasing value to its investors.
OPKO To Announce Second Quarter Operating and Financial Results on August 5, 2015 more »
FDA Accepts OPKO's New Drug Application for Rayaldee(TM) more »
OPKO Announces Completion of Enrollment in Phase 3 Trial of hGH-CTP in Growth Hormone Deficient Adults more »
OPKO Health is an opportunistic research and development company that targets large, high-growth markets.